Can a simple device improve dialysis? small study tests HemoCept
NCT ID NCT07217470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed pilot study tested whether the HemoCept device can accurately measure fluid removal during dialysis in 26 adults with end-stage kidney disease. Researchers compared device readings before and after dialysis to changes in dry weight. The goal is to see if this non-invasive tool could help doctors better manage fluid balance during treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HemoCept device
- What this could lead to
- If successful, this could lead to a non-invasive way to monitor fluid removal during dialysis, improving treatment precision.
- What could go wrong
- This is a small pilot study with only 26 participants, so results may not apply to everyone. The device is still experimental and may not prove accurate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESRD (END STAGE RENAL DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sierra Nevad Specialty Care
Reno, Nevada, 89511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which nerve block offers better pain control for dialysis access surgery?
- Could a milk protein help dialysis patients fight anemia?
- New dialysis gadget aims to clean blood better and boost life quality
- New catheter coating could cut dialysis complications
- Can a phone app keep dialysis patients out of the hospital?
- Blood test may spot muscle wasting in dialysis patients